Alaska Tuberculosis Program Manual - Epidemiology - State of Alaska
Alaska Tuberculosis Program Manual - Epidemiology - State of Alaska Alaska Tuberculosis Program Manual - Epidemiology - State of Alaska
First-Line TB Drugs The first-line drugs commonly used in the treatment of pediatric TB diseases, their doses and side effects are summarized in Table 10. A L A S K A T U B E R C U L O S I S P R O G R A M M A N U A L Diagnosis and Treatment of LTBI and TB Disease in Children 9.26 R e v i s e d N o v e m b e r 2 0 1 2
† 35 Table 11: DOSES*OF FIRST-LINE ANTITUBERCULOSIS DRUGS FOR ADULTS AND CHILDREN Doses (maximum) Drug Preparation Adult/Child* Daily 1 x weekly 2 x weekly 3 x weekly Tablets (50, 100, 300 mg); Adults 5 mg/kg (300 mg) 15 mg/kg (900 mg) 15 mg/kg (900 mg) 15 mg/kg (900 mg) Isoniazid Rifampin Elixir (50 mg/5 ml); Aqueous IV/IM solution (100 mg/ml) Capsule (150, 300 mg); suspend powder for PO; Aqueous IV solution Rifapentine Tablet (150 mg) Pyrazinamide Tablet (500 mg) Ethambutol Tablet (100 and 400 mg) Children 10-15 mg/kg (300 mg) ---- 20-30 mg/kg (900 mg) ---- Adults ❶ 10 mg/kg (600 mg) A L A S K A T U B E R C U L O S I S P R O G R A M M A N U A L Diagnosis and Treatment of LTBI and TB Disease in Children 9.27 R e v i s e d N o v e m b e r 2 0 1 2 ---- 10 mg/kg (600 mg) 10 mg/kg (600 mg) Children 10-20 mg/kg (600 mg) ---- 10-20 mg/kg (600 mg) ---- Adults ---- 10 mg/kg (600 mg); continuation phase only --- --- Children Not approved Not approved Not approved Not approved Adults 40-55 kg 1,000 mg 56-75 kg 1,500 mg 76-90 kg 2,000 mg ---- 40-55 kg 2,000 mg 56-75 kg 3,000 mg 76-90 kg 4,000 mg Children 15-30 mg/kg (2,000 mg) ---- 50 mg/kg (2,000 mg) ---- Adults 40-55 kg 800 mg 56-75 kg 1,200 mg 76-90 kg 1,600 mg ---- 40-55 kg 2000 mg 56-75 kg 2,800 mg 76-90 kg 4,000 mg Children 15-20 mg/kg (1000 mg) ---- 50 mg/kg (2.5 gm) ---- ❶ Dose may need to be adjusted when there is concomitant treatment for HIV/AIDS. *Children weighing more than 40 kg (88 pounds) should be dosed as adults 40-55 kg 1,500 mg 56-75 kg 2,500 mg 76-90 kg 3,000 mg 40-55 kg 1,200 mg 56-75 kg 2,000 mg 76-90 kg 2,400 mg
- Page 157 and 158: Policy Detailed information on the
- Page 159 and 160: Window period prophylaxis is treatm
- Page 161 and 162: Regimens Identify an appropriate re
- Page 163 and 164: Dosages Once the appropriate regime
- Page 165 and 166: Side Effects and Adverse Reactions
- Page 167 and 168: If a patient reports to a healthcar
- Page 169 and 170: Antituberculosis Drug Rifampin (RIF
- Page 171 and 172: DOT is strongly encouraged for thos
- Page 173 and 174: Table 7 describes the duration of t
- Page 175 and 176: Alcoholism Alcohol-Related Treatmen
- Page 177 and 178: Medication Administration and Pharm
- Page 179 and 180: National Tuberculosis Controllers A
- Page 181 and 182: 24 CDC . “Recommendations for Use
- Page 183 and 184: Diagnosis and Treatment of Latent T
- Page 185 and 186: All children suspected or diagnosed
- Page 187 and 188: Latent Tuberculosis Infection (LTBI
- Page 189 and 190: History of BCG vaccination is not a
- Page 191 and 192: Because of their higher specificity
- Page 193 and 194: Table 3: COUNTRIES AND AREAS WITH A
- Page 195 and 196: Treatment of Latent TB Infection (L
- Page 197 and 198: For consultation regarding the trea
- Page 199 and 200: Monitoring DOT is mandatory for INH
- Page 201 and 202: For young infants, some experts rec
- Page 203 and 204: TABLE 8: SIGNS AND SYMPTOMS OF PULM
- Page 205 and 206: Treatment of Tuberculosis Basic pri
- Page 207: Regime n 1 2 3 ❺ Table 10: FOUR T
- Page 211 and 212: Monitoring Response to Treatment Ch
- Page 213 and 214: Child Care and Schools: Children wi
- Page 215 and 216: Other TB medications are not commer
- Page 217 and 218: 10 Centers for Disease Control and
- Page 219 and 220: Case Management CONTENTS Introducti
- Page 221 and 222: patient-centered approach to case m
- Page 223 and 224: Alaska TB Program: Timeline for the
- Page 225 and 226: For assistance with language issues
- Page 227 and 228: Ascertain the extent of TB illness
- Page 229 and 230: medical/health problem. The date of
- Page 231 and 232: necessary to teach people how to ta
- Page 233 and 234: Treatment Plan Components Recommend
- Page 235 and 236: Implementation Activities To begin
- Page 237 and 238: o Indicate the number of doses prov
- Page 239 and 240: Review the status of the contact in
- Page 241 and 242: For more information, see the “Di
- Page 243 and 244: importance of continued treatment a
- Page 245 and 246: 5. Review information with the prov
- Page 247 and 248: Completion of Therapy The case mana
- Page 249 and 250: Case Closures Other than Completion
- Page 251 and 252: Conduct a case management meeting o
- Page 253 and 254: Biweekly (BIW) doses of TB medicati
- Page 255 and 256: Use DOT with other measures such as
- Page 257 and 258: It is important not to send a mixed
First-Line TB Drugs<br />
The first-line drugs commonly used in the treatment <strong>of</strong> pediatric TB diseases, their doses and<br />
side effects are summarized in Table 10.<br />
A L A S K A T U B E R C U L O S I S P R O G R A M M A N U A L Diagnosis and Treatment <strong>of</strong> LTBI and TB Disease in Children 9.26<br />
R e v i s e d N o v e m b e r 2 0 1 2
Change language